Skip to main content

Advertisement

Contact Wenxiong Zhang

From: Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis

Contact corresponding author